XOMA Royalty Declares Quarterly Preferred Stock Dividends
19 déc. 2024 07h30 HE
|
XOMA Royalty Corporation
XOMA Royalty January 2025 Dividend Record and Payment Dates
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
02 déc. 2024 07h30 HE
|
XOMA Corporation
Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and...
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
07 nov. 2024 07h30 HE
|
XOMA Corporation
Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s...
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
22 oct. 2024 08h00 HE
|
XOMA Corporation
XOMA Royalty acquires 50% economic interest in portfolio of 60-plus early-stage assets with $15M payment to Twist Bioscience
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
23 sept. 2024 06h30 HE
|
XOMA Corporation
MIPLYFFA(TM) becomes 6th commercial asset in XOMA Royalty's portfolio
XOMA Royalty Declares Quarterly Preferred Stock Dividends
23 sept. 2024 05h30 HE
|
XOMA Corporation
October 2024 Dividends on Perpetual Preferred Shares
XOMA Royalty to Present at Upcoming Investor Conferences in September
04 sept. 2024 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the...
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
13 août 2024 07h30 HE
|
XOMA Corporation
Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the...
XOMA Declares Quarterly Preferred Stock Dividends
20 juin 2024 07h30 HE
|
XOMA Corporation
July 2024 Dividends
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
12 juin 2024 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta...